Importation, Pay-For-Delay Reform Backed By Biden Order; March-In Rights For Pricing Suggested
The policies have long been Democratic priorities, but of the three, the order’s implicit support for march-in rights might lead to the biggest change.
You may also be interested in...
India’s draft policy to catalyze R&D and innovation seeks to create a “regulatory bias” towards innovation and aims to cut approval timelines sharply, among a raft of other proposals that include enabling differential pricing for “innovation with therapeutic benefits.” The Pink Sheet explores multiple nuances of the plan with industry experts.
After months of reticence about his Administration's plans for tackling drug pricing, Biden's executive order offers some clues about what might be in store and what kind of timeline they are working with.
Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.